Evaxion Biotech A/S (NASDAQ:EVAX) concluded the trading at $2.33 on Wednesday, September 21 with a rise of 22.63% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $1.90 with its price kept floating in the range of $2.15 and $3.5199 on the day. Considering stock’s 52-week price range provides that EVAX hit a high price of $25.04 and saw its price falling to a low level of $1.51 during that period. Over a period of past 1-month, stock came subtracting -13.70% in its value.
With its current market valuation of $55.52 million, Evaxion Biotech A/S is set to declare its quarterly results on Apr 04, 2022 – Apr 08, 2022. Analysts are in estimates of -$0.3 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$1.25 for 2022 with estimates of that growing to -$1.47 in next year. These estimates are suggesting current year growth of 0.80% for EPS and -17.60% growth next year.
In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review EVAX stock’s current outlook then short term indicators are assigning it an average of 50% Sell, while medium term indicators are categorizing the stock at an average of Hold. Long term indicators are suggesting an average of 50% Sell for it.
According to ratings assigned by 3 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 0 of them are recommending Evaxion Biotech A/S (EVAX) as a Hold, while 3 are in view that stock is a Buy. Recommendation by 0 analysts for the stock is an Underweight while number of those analysts who rated the stock as an Overweight is 0, whereas 0 of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Overweight and that encourages the investors to exploit the opportunity and build their stake up in the company.
Digging deeper we become aware of the PEG ratio of the EVAX stock which is currently positioned at 0. It further provides that stock’s current price level is 5.64% away from its 20-day simple moving average and is -8.37% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 52.50 while volatility remained at 17.43% over the past week which changes to 11.45% when measuring it over the past month. Average true range or ATR is currently at 0.28. In predicting price targets of as low as $16.00 and as high as $18.00, analysts are in agreement on assigning the stock over the next 12 months average price target of $17.33. Stock’s current price level is -586.7% above from estimated low price target while it is -672.53% below the estimated high; and even if the EVAX’s share succeeded to reach the median price of $18.00, then the outlook of -672.53% could come to the excitement of the investors.
Having a second look at Evaxion Biotech A/S (NASDAQ:EVAX) provides that stock’s average daily trading volume for 3 months was 31.49K, while it jumped to 4.63 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 23.84 million.
The percentage of outstanding shares held by the insiders is 42.47% while it is 1.00% for the institutional holders. The figures also indicate that as of Aug 30, 2022, number of stock’s short shares was 0.18 million which implies a short ratio of 8.36. This shows down a 0.77% of Short Interest in company’s outstanding shares on the day. In August the standing of shares short improved as it was 0.19 million in the previous month. Subtraction of -47.29% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.